Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Int.biotech. (IBT) Share Price

Price 910.00p on 12-02-2026 at 12:54:14
Change 14.00p 1.56%
Buy 916.00p
Sell 906.00p
Last Trade: Sell 3,400.00 at 907.5524p
Day's Volume: 95,614
Last Close: 896.00p
Open: 902.00p
ISIN: GB0004559349
Day's Range 902.00p - 918.00p
52wk Range: 480.00p - 1,000.00p
Market Capitalisation: £290.32m
VWAP: 910.44857p
Shares in Issue: 31.90m

Int.biotech. (IBT) Latest Trades

Buy/Sell Volume Trade Prc Trade Type Trade Time
Sell* 3,400 907.5524p Ordinary
12:37:46 - 12-Feb-26
Buy* 1 915.00p Ordinary
12:36:30 - 12-Feb-26
Sell* 3,400 909.3383p Ordinary
12:27:53 - 12-Feb-26
Buy* 24 914.00p SI Trade
12:27:03 - 12-Feb-26
Buy* 3,000 912.40p Ordinary
12:17:45 - 12-Feb-26
Buy* 548 912.2902p Ordinary
12:04:56 - 12-Feb-26
Buy* 3,000 912.40p Ordinary
12:04:23 - 12-Feb-26
Buy* 4,000 912.30p Ordinary
11:45:24 - 12-Feb-26
Sell* 81 909.51p Ordinary
11:37:22 - 12-Feb-26
Buy* 4,000 912.30p Ordinary
11:35:40 - 12-Feb-26
See more Int.biotech. trades

Int.biotech. (IBT) Share Price History

Time period:
to
Date Open High Low Close Volume
12th Feb 2026 (Thu) 902.00 918.00 902.00 896.00 95,614
11th Feb 2026 (Wed) 904.00 920.00 894.00 896.00 56,033
10th Feb 2026 (Tue) 912.00 924.00 910.00 916.00 55,168
9th Feb 2026 (Mon) 910.00 914.00 900.00 912.00 53,195
6th Feb 2026 (Fri) 914.00 914.00 874.00 904.00 132,416
5th Feb 2026 (Thu) 930.00 936.00 918.00 918.00 47,121
4th Feb 2026 (Wed) 942.00 942.00 930.00 930.00 40,011
3rd Feb 2026 (Tue) 944.00 950.00 938.00 946.00 53,789
2nd Feb 2026 (Mon) 912.00 944.00 912.00 936.00 76,242
30th Jan 2026 (Fri) 930.00 930.00 914.00 918.00 83,252
29th Jan 2026 (Thu) 940.00 942.00 926.00 930.00 97,993
28th Jan 2026 (Wed) 952.00 956.00 940.00 940.00 70,909
27th Jan 2026 (Tue) 954.00 962.00 950.00 954.00 61,176
26th Jan 2026 (Mon) 974.00 974.00 950.00 958.00 106,789
23rd Jan 2026 (Fri) 992.00 994.00 980.00 980.00 83,485
22nd Jan 2026 (Thu) 980.00 990.00 972.00 982.00 56,370
21st Jan 2026 (Wed) 964.00 970.00 962.00 970.00 40,180
20th Jan 2026 (Tue) 950.00 964.00 942.00 964.00 82,263
19th Jan 2026 (Mon) 960.00 964.00 952.00 960.00 103,581
16th Jan 2026 (Fri) 966.00 974.00 964.00 970.00 64,502
15th Jan 2026 (Thu) 970.00 986.00 966.00 972.00 67,590
14th Jan 2026 (Wed) 962.00 968.00 956.00 968.00 76,946
13th Jan 2026 (Tue) 964.00 966.00 954.00 954.00 69,060
12th Jan 2026 (Mon) 970.00 976.00 956.00 968.00 85,003
See more Int.biotech. price history

Int.biotech. (IBT) Regulatory News

Date Source Headline
11th Feb 2026 11:24 am RNS Net Asset Value(s)
10th Feb 2026 12:02 pm RNS Restatement of Net Asset Value(s)
10th Feb 2026 11:41 am RNS Net Asset Value(s)
9th Feb 2026 11:55 am RNS Net Asset Value(s)
6th Feb 2026 12:13 pm RNS-R Virtual Outlook Presentation
6th Feb 2026 11:50 am RNS Net Asset Value(s)
5th Feb 2026 11:36 am RNS Net Asset Value(s)
4th Feb 2026 11:44 am RNS Net Asset Value(s)
3rd Feb 2026 11:56 am RNS Net Asset Value(s)
2nd Feb 2026 11:58 am RNS Net Asset Value(s)
See more Int.biotech. regulatory news

Int.biotech. (IBT) Share News

UK dividends calendar - next 7 days

16th Jan 2026 15:52

Read More

UK dividends calendar - next 7 days

22nd Dec 2025 14:43

Read More

International Biotechnology beats benchmark with 0.7% NAV gain

6th Nov 2025 19:17

(Alliance News) - International Biotechnology Trust PLC on Thursday said its portfolio continued to outperform the sector benchmark as the company reported full-year results. Read More

IN BRIEF: International Biotechnology Trust notes Novo to buy Akero

9th Oct 2025 15:40

International Biotechnology Trust PLC - investor in biotech and life science companies - Notes portfolio firm Akero Therapeutics Inc as agreed to be taken over by Novo Nordisk AS in a deal worth up to EUR5.2 billion. Novo Nordisk will pay an initial USD54 per share, with a contingent portion of the deal worth USD6 per share. The Bagsvaerd, Denmark-based pharmaceuticals company will pay an initial EUR4.7 billion to buy the firm, and a potential additional payment of EUR500 million, hinging on US regulatory approval for key Akero treatment Efruxifermin. The deal adds Akero's Efruxifermin to Novo Nordisk's portfolio. The asset is aimed at treating metabolic dysfunction-associated steatohepatitis, a disease caused by fat buildup in the liver. Read More

International Biotechnology to raise unquoted exposure with Schroders

2nd Oct 2025 13:31

(Alliance News) - International Biotechnology Trust PLC on Thursday said it has partnered with Schroders Capital to access more investees in the earlier stages of development. Read More

See more Int.biotech. news
FTSE 100 Latest
Value10,484.06
Change11.95

Login to your account

Forgot Password?

Not Registered